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Pacemaker infections are a complication with an incidence
rate of 0.8—5.7% and are usually associated with recent
manipulations.1 Mucormycosis endocarditis is extremely
rare. We describe herein a female patient with essential
thrombocytosis, who suffered frommucormycosis of the lead
of a permanent pacemaker. The final diagnosis was made
postoperatively.
An 80-year-old woman with a permanent pacemaker
(implanted three years previously due to complete atrioven-
tricular block) and an 8-year history of essential thrombocy-
tosis treated with hydroxyurea (500 mg once a day) was
admitted to hospital with fatigue, low-grade fever, and
exertion dyspnea. She had a history of chronic obstructive
pulmonary disease and previous ischemic stroke. Blood ana-
lysis revealed anemia and elevated erythrocyte sedimenta-
tion rate, C-reactive protein, and lactate dehydrogenase. On
chest X-ray there was a consolidation of the right lower lobe.
Transthoracic (TTE) and transesophageal (TEE) echocardio-
grams showed a largemass in the right atrium attached to the
lead, and stenosis of the tricuspid valve (Figure 1A). Blood
cultures were negative and the patient was treated with
ceftriaxone, amikacin, and vancomycin.
Due to the lack of clinical improvement in the patient and
the increased size of the vegetation, caspofungin was added
and surgical removal of the infected lead was planned. The
entire pacemaker system was successfully removed using
cardiopulmonary bypass. There was no evidence of infection
or necrosis in the myocardium and the tricuspid valve was
normal. Cultures of valvular tissue specimens on Sabouraud
dextrose agar, on day 2 of incubation at 25 8C, yielded rich and
pure growth of cotton-like colonies. Microscopic examination
by the lactophenol blue method revealed wide, sparsely sep-
tated hyphae and mostly branched sporangiophores bearing
terminal spherical, dark pigmented sporangia (Figure 1B) —
features considered consistent with the typical Mucor spp
morphology. Definitive identification to the species level
was further assisted by determination of the fungus’ carbon
assimilation profile using the ID 32C system (bioMerieux,Marcy
l’Etoile, France). Antifungal susceptibility testing was per-1201-9712/$32.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.03.034formed by means of the E-test assay (AB Biodisk, Sweden).
Despite the lack of established interpretative breakpoints,
amphotericin B demonstrated the most potent effect (mini-
mum inhibitory concentration (MIC) = 0.125 mg/ml), while
amongst the azoles tested, posaconazole, which has recently
been introduced in clinical practice, exhibited good in vitro
activity (MIC = 0.125 mg/ml).2
Sputum cultures were negative, but it was assumed that
the consolidation of the right lower lobe was also part of the
mucormycosis (probably as part of septic emboli). Therapy
was changed to liposomal amphotericin B (AmBisome) at a
dose of 7 mg/kg. Despite treatment, the patient developed
multiple organ failure, which led to death five days after the
operation.
Endocarditis due to fungal infection is an uncommon
occurrence but is considered to be the most severe form
of infective endocarditis. Characteristics of fungal endocar-
ditis include large vegetations, with an increased potential of
embolization, a tendency to grow on prosthetic valves, and a
poor outcome despite adequate medical and surgical treat-
ment.3 The possibility of fungal endocarditis must always be
taken into account in patients with large vegetations and
negative blood cultures.
Primary cardiovascular mucormycosis is very rare and
usually results in death within a short time. It is thought
to be related to immunosuppression secondary to severe
concomitant diseases. Major predisposing factors for mucor-
mycosis are diabetes mellitus, hematologic malignancies,
long-term therapy with corticosteroids or deferoxamine,
metabolic acidosis, and AIDS. It is very difficult to find
microbiological evidence in blood, and most cases are diag-
nosed postoperatively or postmortem. Amphotericin B is still
the therapy of choice combined with surgical treatment.4
Surgery is mandatory for the treatment of mucormycosis. In
all successful cases in the literature patients had extensive
surgery of the infected area. In the literature, successful
treatment of mucormycosis endocarditis has been reported
in only three cases.5 In these cases patients were younger,
had septic emboli, and in all the underlying illness was
hematologic malignancy (maybe greater suspicion). Therapy
was combined surgery and liposomal amphotericin B.
We must always suspect fungal endocarditis in patients at
high risk (malignancy, corticosteroids, diabetes mellitus,
large vegetations). If there is a suspicion of fungal endocar-
ditis and especially mucormycosis, antifungal therapy must
be started pre-operatively. In the era of new antifungalPublished by Elsevier Ltd. All rights reserved.
Figure 1 (A) Transesophageal echocardiogram (TEE) showing a
large mass in the right atrium (arrow) attached to the pacemaker
lead. (B) Hyphal elements and sporangiophores forming terminal
globose sporangia by lactophenol blue microscopy (40).
e152 Correspondencedrugs, a lipid formulation of amphotericin B should still be
the drug of choice for empirical therapy of fungal endocar-
ditis despite the fact that endocarditis due to Mucor spp is
extremely rare.
Acknowledgments
We would like to thank Stella Alexiou-Daniel, Professor of
Microbiology, for her contribution to this work.
Conflict of interest: No conflict of interest to declare.References
1. Duval X, Selton-Suty C, Alla F, Salvador-Mazenq M, Bernard Y,
Weber M, et al. Endocarditis in patients with a permanent pace-
maker: a 1-year epidemiological survey on infective endocarditis
due to valvular and/or pacemaker infection. Clin Infect Dis
2004;39:68—74.
2. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In
vitro activities of posaconazole, itraconazole, voriconazole,
amphotericin B, and fluconazole against 37 clinical isolates of
zygomycetes. Antimicrob Agents Chemother 2002;46:1581—2.
3. Jackman Jr JD, Simonsen RL. The clinical manifestations of
cardiac mucormycosis. Chest 1992;101:1733—6.
4. Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ,
Graybill JR, et al. Treatment of 21 cases of invasive mucormycosis
with amphotericin B colloidal dispersion. Eur J Clin Microbiol
Infect Dis 2001;20:460—6.
5. Gubarev N, Separovic J, Gasparovic V, Jelic I. Successful treat-
ment of mucormycosis endocarditis complicated by pulmonary
involvement. Thorac Cardiovasc Surg 2007;55:257—8.
Simeon Metallidis*
Theofilos Chrysanthidis
Pavlos Nikolaidis
1st Internal Medicine Department,
Infectious Diseases Division,
AHEPA University Hospital,
1 Stilponos Kyriakidi Str,
PO 54006, Thessaloniki, Greece
Evangelos Kazakos
Microbiology Department,
AHEPA University Hospital,
Thessaloniki, Greece
Antnan Saraf
Cardio-surgical Department,
AHEPA University Hospital,
Thessaloniki, Greece
*Corresponding author. Tel.: +30 2310 994619;
fax: +30 2310 994615
E-mail address: metallidissimeon@yahoo.gr
(S. Metallidis)
18 August 2007
